Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

Cancer Clinical Trial

Official title:

A Single-Center Exploratory Clinical Study to Evaluate the Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05141253
• Other study ID #: 2021-TJ-CART
• Status: Recruiting
• Phase: Early Phase 1
• Start date: January 12, 2022
• Est. completion date: November 1, 2036

Study information

• Verified date: April 2022
• Source: Tongji Hospital
• Contact: Qinglei Gao, MD. PhD
• Phone: 15391566981
• Email: qingleigao[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single-center exploratory clinical trial. It is estimated that 9-24 subjects will be enrolled. The "3+3" dose escalation design is adopted. The main purpose is to evaluate the safety of RD133 in the treatment of subjects with relapsed or refractory MSLN-positive solid tumors and explore the Recommend phase II dose of RD133 in the treatment of patients with relapsed/refractory MSLN-positive solid tumors.

Description:

Leukapheresis procedure will be performed to manufacture RD133 chimeric antigen receptor (CAR) modified T cells. Bridging therapy is allowed between PBMC collection and lymphodepletion. Lymphodepletion with fludarabine and cyclophosphamide was performed for three consecutive days. After 1-day rest, subjects will receive a single dose infusion of RD133 at 1.0, 3.0, or 6.0x 10^6 CAR+ T cells/Kg. Subjects will be followed in the study for a minimum of 2 years after RD133 infusion. Long-term follow-up for lentiviral vector safety will be followed for up to 15 years after RD133 infusion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: November 1, 2036
• Est. primary completion date: November 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The subject must personally sign the written informed consent form approved by the ethics committee before the start of the study;

2. 2.=18 years of age;

3. Have received at least 2 prior standard treatments, and achieved no response to the last-line treatment;

4. >25% Mesothelin positive rate on tumor cell membrane confirmed by prior immunohistochemistry of tumor tissue or freshly punctured tissue;

5. Expected survival = 12 weeks;

6. ECOG score = 2;

7. At least one measurable target lesion that meets the RECIST v1.1 standard;

8. Female or male subjects with fertility should agree to practice an effective method of contraception from the day of signing the ICF until 365 days after the infusion. Effective method of contraception is defined as: abstinence or contraceptive methods with an annual failure rate of <1% specified in the plan;

9. Before being enrolled in the group, the subject must have proper organ function and meet all of the following criteria: 9.1 The absolute value of neutrophils=1.0×10^9/L (granulocyte colony stimulating factor (G-CSF) support is allowed, but must be without supportive treatment within 7 days before the examination); 9.2 Platelet count =75×10^9/L (must be without blood transfusion support [including blood component transfusion] or thrombopoietin [TPO], or other treatments for the purpose of increasing platelets within 7 days before the examination); 9.3 Hemoglobin =9g/dl (must be without blood transfusion support [including blood component transfusion] within 7 days before the examination); 9.4 Bilirubin value =1.5×upperlimit of normal (ULN) (except bile duct obstruction caused by tumor compression); 9.5 Creatinine clearance rate =60 ml/min; 9.6 ALT or AST=2.5×upper limit of normal (ULN) (with liver involvement =5×ULN); 9.7 The results of echocardiography indicate that the cardiac ejection fraction is = 50%,without obvious pericardial effusion; 9.8 Stable coagulation function: INR = 1.5,APTT =1.2×ULN (except tumor-related anticoagulation therapy); 9.9 >91% basic blood oxygen saturation in the natural indoor air environments.

Exclusion Criteria:

1. Subject who has received any of the following prior treatments:

1.1 Subject with acute or chronic graft-versus-host disease (GVHD) who need systemic treatment within 4 weeks before enrollment; 1.2 Subject who has received gene therapy before enrollment; 1.3 Subject who needs systematic immunosuppressive therapy (except topical drugs) to control autoimmune diseases (eg: Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.), immunodeficiency or other diseases in the first 2years after enrollment; 1.4 Subject who has been injected with live vaccines within 4 weeks before enrollment; 1.5 Subject has received other interventional clinical research drugs within 12 weeks before apheresis.

2. Subject with central metastasis or complete intestinal obstruction;

3. Subject with moderate or more severe hydrothorax and ascites which are hard to control by conventional treatment and require continuous catheter drainage;

4. With an active malignant tumor in the past 5 years, unless it is a curable tumor and has been obviously cured, such as basal or squamous cell carcinoma, cervical or breast carcinoma in situ, etc.

5. Subject with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and abnormal HBV DNA test results in peripheral blood(abnormal HBV DNA test results are defined as: HBV DNA quantitative level higher than the lower limit of the detection center or higher than normal range of the detection center; or qualitative HBV DNA test positive);Hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA positive; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus ( CMV) DNA test positive; syphilis test RPR positive.

6. With an uncontrollable active infection (except genitourinary system infection and upper respiratory tract infection <CTCAE Grade 2).

7. Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification = grade 3), severe arrhythmia.

8. Subject with hypertension that cannot be controlled by medication.

9. The toxicity of previous treatment has not been relieved to baseline or =1(NCI-CTCAE v5.0, except for hair loss and laboratory abnormalities without clinical significance).

10. Major surgery within 2 weeks before enrollment, or has surgery planned during the time the subject is expected to be infused with RD133 or within12 weeks after RD133 infusion (except planned surgery under local anesthesia).

11. Subject who has a solid organ transplant.

12. Women who are pregnant or breastfeeding.

13. Subject with previous central nervous system diseases (such as cerebral aneurysm, epilepsy, stroke, Alzheimer's disease, mental illness, etc.) or mental disorders.

14. Other unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney, or metabolic diseases that require medication.

15. Known to have life-threatening allergic reactions, hypersensitivity reactions or intolerances to RD133 cell preparations or its components.

16. Subject with hemorrhage, severe thrombosis judged by the Investigator, or hereditary/acquired hemorrhage and severe thrombosis (including hemophilia, coagulopathy, thrombocytopenia, hypersplenism, etc.), or are receiving thrombolytic or anticoagulant.

17. The researcher believes that other situations are not suitable for inclusion in the group.

Related Conditions & MeSH terms

• Cancer

Intervention

Drug:
• RD133
The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFßRII receptors. dnTGFßRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.

Locations

Country	Name	City	State
China	Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (2)

Lead Sponsor	Collaborator
Tongji Hospital	Shanghai IASO Biotechnology Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	TGF-ß level in peripheral blood.	TGF-ß levels in peripheral blood after RD133 infusion.	Maximum of 5 years post infusion
Other	The expression of CD3, CD4, CD8, CD68, CD163, MSLN, and PDL1	The expression of CD3, CD4, CD8, CD68, CD163, MSLN, and PDL1 in tumor tissue after RD133 cell infusion measured by Immunohistochemistry.	Maximum of 5 years post infusion
Other	The positive rate of human anti-RD133 antibodies after RD133 cell infusion	The proportion of patients with serum anti-RD133 antibodies after RD133 cell infusion	Maximum of 5 years post infusion
Other	MSLN level in peripheral blood and in tumor tissues	MSLN level in peripheral blood and in tumor tissues before and after RD133 cell infusion.	Maximum of 5 years post infusion
Other	The positive rate in replication competent lentivirus (RCL).	The proportion of patients with detectable replication competent lentivirus after RD133 cell infusion	Maximum of 5 years post infusion
Other	T/B/NK cell ratio in peripheral blood after RD133 cell infusion.	The ratio of T cell and B cell, T cell and NK cell, B cell and NK cell in peripheral blood after RD133 cell infusion.	Maximum of 5 years post infusion
Other	Levels of inflammatory factors in peripheral blood after RD133 cell infusion.	Levels of inflammatory factors (including but not limited to CRP, IL-6, IL-10) in peripheral blood after RD133 cell infusion.	Maximum of 5 years post infusion
Primary	Dose-limiting toxicity (DLT)	Type and incidence of dose-limiting toxicity (DLT) by dose group	Maximum of 5 years post infusion
Primary	Adverse events (AEs) and serious adverse events (SAEs)	Type and incidence of adverse events (AEs) and serious adverse events (SAEs) by dose group	Maximum of 5 years post infusion
Secondary	Number of Participants With Abnormal Laboratory Values	Number of Participants With Abnormal results (including laboratory tests, vital signs, physical examinations, ECG and other safety-related tests).	Maximum of 5 years post infusion
Secondary	Objective response rate (ORR)	The proportion of subjects who have achieved best response of partial response (PR) or complete response (CR) according to the RECIST V1.1evaluation criteria 3 months after RD133 cell infusion.	Maximum of 5 years post infusion
Secondary	Duration of response (DoR)	The time from the date of initial documentation of CR/PR after RD133 cell infusion to the date of progressive disease or death due to the disease studied	Maximum of 5 years post infusion
Secondary	Time to response (TTR)	The time from the date of RD133 cell infusion to the first efficacy evaluation of partial response (PR) or complete response (CR)	Maximum of 5 years post infusion
Secondary	Disease control rate (DCR)	The proportion of subjects with best efficacy assessment of complete response (CR), partial response (PR) or stable disease (SD)	Maximum of 5 years post infusion
Secondary	Progression-free survival (PFS)	The time from the date of RD133 cell infusion to the date of initial documentation of progressive disease/relapse or death from any cause.	Maximum of 5 years post infusion
Secondary	Overall survival (OS)	The time from the date of RD133 cell infusion to the date of death.	Maximum of 5 years post infusion
Secondary	Maximum Plasma Concentration [Cmax] of RD133 in vivo	Maximum Plasma Concentration [Cmax] of CAR T cell concentration in peripheral blood and tumor tissue (if any) after RD133 infusion.	Maximum of 5 years post infusion
Secondary	Minimum Plasma Concentration [Cmin] of RD133 in vivo	Minimum Plasma Concentration [Cmin] of CAR T cell concentration in peripheral blood and tumor tissue (if any) after RD133 infusion.	Maximum of 5 years post infusion